In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Kahn serves as an advisory panel member/consultant for Abarceo Pharma, Amgen, AltPep, Anji, Biomea Fusion, Eli Lilly and Company, Merck, Neurimmune, Novo Nordisk, and Oramed and receives research ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Third Quarter 2024 Results Key Financial Results Revenue: US$182.5m (up 48% ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

Revenue Guidance: Increased to $675 to $700 million for 2024. Corcept Therapeutics Inc (NASDAQ:CORT) reported a 48% increase in revenue for the third quarter of 2024, reaching $182.5 million. The ...